RWE About QOL and Compliance of Patients With OFS in China

CompletedOBSERVATIONAL
Enrollment

562

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Breast CancerQuality of LifeHormone Receptor-positive Breast Cancer
Interventions
DRUG

3M GnRHa

This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).

DRUG

1M GnRHa

This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER